HEALWELL AI: HEALWELL's DARWEN to Power AI-Driven Clinical Trial Matching for WELLTRUST, a Network of Over 100,000 Consented Patients

HEALWELL AI Inc. (TSX:AIDX, OTCQX:HWAIF) reported Q2-2026 revenue from continuing operations of $33.0 million, roughly flat vs. $33.2 million in Q2-2025. Six-month revenue rose to $66.2 million from $41.2 million, driven by the Orion Health acquisition. Operating cash flow was $4.5 million positive. The company valued its indirect SpaceX stake at about CAD$23 million and targets ~10% Adjusted EBITDA margin by year-end.

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

Microsoft's Xbox reportedly turned down a $500 million Netflix deal for exclusive rights to its IP, asking for $800 million instead. Netflix withdrew the offer. Xbox denies the deal's failure, citing other partnerships and record interest in its IP. The company is now pursuing smaller deals with multiple partners. According to an industry insider, this may have led to the creation of a new cross-media department.

Moderna's INTerpath-001 trial showed improved recurrence-free and distant-metastasis-free survival for intismeran plus pembrolizumab versus pembrolizumab alone in resected melanoma. The combination had similar serious adverse event rates, with overall survival follow-up ongoing, according to the company.

Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.

Apple launched its first folding iPhone, the $1,999 Duo, with deliveries starting January 25. The premium model, priced at $3,199, is expected to be the best-selling in the niche market. Apple enters the foldable phone sector, competing with Samsung and Chinese manufacturers.